Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.

Østergren PB, Kistorp C, Fode M, Bennedbaek FN, Faber J, Sønksen J

BJU international28 Nov 2018Cited by 32 (Europe PMC)

PMID30388320DOI10.1111/bju.14609PepBankPUB-30388320

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, fasting glucose changes did not differ significantly between triptorelin and orchiectomy.
In plain wordsIn men with advanced prostate cancer, fasting blood sugar changes did not differ significantly between triptorelin and orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFasting plasma glucose change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Measurements
Between-treatment difference in fasting plasma glucose change
0.2 mmol/L
treatment comparison as reported
Source sentences
Summary
No treatment differences in the changes in fasting plasma glucose (0.2 mmol/L, 95% confidence interval [CI] -0.1, 0.4; P = 0.32) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832001
02HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, total fat mass increased less with triptorelin than with orchiectomy at 48 weeks.
In plain wordsIn men with advanced prostate cancer, total body fat increased less with triptorelin than with orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTotal fat mass change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Measurements
Excess fat mass increase
2.06 kg
orchiectomy versus triptorelin at 48 weeks
Source sentences
Summary
The orchiectomy group experienced greater increases in total fat mass (+2.06 kg, 95% CI 0.55, 3.56), SAT (+133 cm³ , 95% CI 22, 243) and weight (+3.30 kg, 95% CI 0.74, 5.87) at 48 weeks than did the triptorelin group (all P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832002
03HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, subcutaneous fat increased less with triptorelin than with orchiectomy at 48 weeks.
In plain wordsIn men with advanced prostate cancer, fat under the skin increased less with triptorelin than with orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSubcutaneous adipose tissue change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Measurements
Excess SAT increase
133 cm<sup>3</sup>
orchiectomy versus triptorelin at 48 weeks
Source sentences
Summary
The orchiectomy group experienced greater increases in total fat mass (+2.06 kg, 95% CI 0.55, 3.56), SAT (+133 cm³ , 95% CI 22, 243) and weight (+3.30 kg, 95% CI 0.74, 5.87) at 48 weeks than did the triptorelin group (all P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832003
04HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, weight increased less with triptorelin than with orchiectomy at 48 weeks.
In plain wordsIn men with advanced prostate cancer, weight increased less with triptorelin than with orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseWeight change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Measurements
Excess weight increase
3.3 kg
orchiectomy versus triptorelin at 48 weeks
Source sentences
Summary
The orchiectomy group experienced greater increases in total fat mass (+2.06 kg, 95% CI 0.55, 3.56), SAT (+133 cm³ , 95% CI 22, 243) and weight (+3.30 kg, 95% CI 0.74, 5.87) at 48 weeks than did the triptorelin group (all P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832004
05HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, visceral fat changes did not differ between triptorelin and orchiectomy.
In plain wordsIn men with advanced prostate cancer, internal abdominal fat changes did not differ between triptorelin and orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeVisceral adipose tissue change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Source sentences
Summary
No differences in changed VAT, LBM or AG ratio were observed between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832005
06HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, lean body mass changes did not differ between triptorelin and orchiectomy.
In plain wordsIn men with advanced prostate cancer, lean body mass changes did not differ between triptorelin and orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLean body mass change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Source sentences
Summary
No differences in changed VAT, LBM or AG ratio were observed between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832006
07HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, android/gynoid fat ratio changes did not differ between triptorelin and orchiectomy.
In plain wordsIn men with advanced prostate cancer, changes in the abdominal-to-hip fat ratio did not differ between triptorelin and orchiectomy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAndroid/gynoid fat ratio change
Study
n = 58
Comparator
subcapsular orchiectomy
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
22.5 mg/24 week depot injections · 48 weeksAs given in this study (human).
Source sentences
Summary
No differences in changed VAT, LBM or AG ratio were observed between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections.
Summary · context
The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks.
Report a problemFND-3038832007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords